1
|
Bartlett J, Xu K, Wong J, Pond G, Zhang Y, Spears M, Salunga R, Mallon E, Taylor K, Hasenburg A, Markopoulos C, Dirix L, Seynaeve C, van de Velde C, Rea D, Schnabel C, Treuner K, Bayani J. 138MO Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
2
|
Nasr I, McGrath EJ, Harwood CA, Botting J, Buckley P, Budny PG, Fairbrother P, Fife K, Gupta G, Hashme M, Hoey S, Lear JT, Mallipeddi R, Mallon E, Motley RJ, Newlands C, Newman J, Pynn EV, Shroff N, Slater DN, Exton LS, Mohd Mustapa MF, Ezejimofor MC. British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021. Br J Dermatol 2021; 185:899-920. [PMID: 34050920 DOI: 10.1111/bjd.20524] [Citation(s) in RCA: 41] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/26/2021] [Indexed: 12/13/2022]
Affiliation(s)
- I Nasr
- British Association of Dermatologists, Willan House, 4 Fitzroy Square, London, W1T 5HQ, UK
| | - E J McGrath
- Royal Devon and Exeter NHS Foundation Trust, Exeter, EX2 5DW, UK
| | - C A Harwood
- Barts Health NHS Trust, London, E1 1BB, UK.,National Cancer Research Institute's Skin Cancer Clinical Studies Group and Non-Melanoma Skin Cancer Subgroup, London, UK
| | - J Botting
- Royal College of General Practitioners, London, UK
| | - P Buckley
- Independent Cancer Patients' Voice, London, UK
| | - P G Budny
- British Association of Plastic, Reconstructive & Aesthetic Surgeons, London, UK.,Buckinghamshire Healthcare NHS Trust, Aylesbury, HP21 8AL, UK
| | | | - K Fife
- Royal College of Radiologists, London, UK.,Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK
| | - G Gupta
- NHS Lothian, Lauriston Building, Edinburgh, EH3 9EN, UK
| | - M Hashme
- British Association of Dermatologists, Willan House, 4 Fitzroy Square, London, W1T 5HQ, UK
| | - S Hoey
- Royal Victoria Hospital, Belfast, BT12 6BA, UK
| | - J T Lear
- British Society for Skin Care in Immunosuppressed Individuals, London, UK.,Salford Royal NHS Foundation Hospital, Salford, M6 8HD, UK.,Manchester Academic Health Science Centre, Manchester, M20 2LR, UK
| | - R Mallipeddi
- British Society for Dermatological Surgery, London, UK.,St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, SE1 9RT, UK
| | - E Mallon
- St Mary's Hospital, Imperial College Healthcare NHS Trust, London, W2 1NY, UK
| | - R J Motley
- University Hospital of Wales, Cardiff, CF14 4XW, UK
| | - C Newlands
- British Association of Oral and Maxillofacial Surgeons, London, UK.,Royal Surrey County Hospital NHS Foundation Trust, Guildford, GU2 7XX, UK
| | - J Newman
- British Dermatological Nursing Group, Belfast, Ireland.,King's College Hospital NHS Foundation Trust, London, SE5 9RS, UK
| | - E V Pynn
- Nevill Hall Hospital, Abergavenny, NP7 7EG, UK
| | - N Shroff
- Primary Care Dermatology Society, Rickmansworth, UK
| | - D N Slater
- Royal College of Pathologists, London, UK
| | - L S Exton
- British Association of Dermatologists, Willan House, 4 Fitzroy Square, London, W1T 5HQ, UK
| | - M F Mohd Mustapa
- British Association of Dermatologists, Willan House, 4 Fitzroy Square, London, W1T 5HQ, UK
| | - M C Ezejimofor
- British Association of Dermatologists, Willan House, 4 Fitzroy Square, London, W1T 5HQ, UK
| | | |
Collapse
|
3
|
Nicholson P, Wilmot MC, Chan I, Mallon E, Carton J, Hewitt C. A paediatric puzzle: pulsating, pruritic papules and plaques. Clin Exp Dermatol 2018; 44:699-700. [PMID: 30421452 DOI: 10.1111/ced.13830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/29/2018] [Indexed: 11/28/2022]
Affiliation(s)
- P Nicholson
- Dermatology Department, St Mary's Hospital, Imperial College Healthcare Trust, Praed Street, Paddington, London W12 1NY, UK
| | - M-C Wilmot
- Dermatology Department, St Mary's Hospital, Imperial College Healthcare Trust, Praed Street, Paddington, London W12 1NY, UK
| | - I Chan
- Dermatology Department, St Mary's Hospital, Imperial College Healthcare Trust, Praed Street, Paddington, London W12 1NY, UK
| | - E Mallon
- Dermatology Department, St Mary's Hospital, Imperial College Healthcare Trust, Praed Street, Paddington, London W12 1NY, UK
| | - J Carton
- Department of Cellular Pathology, Charing Cross Hospital, Imperial College Healthcare Trust, London, UK
| | - C Hewitt
- Dermatology Department, St Mary's Hospital, Imperial College Healthcare Trust, Praed Street, Paddington, London W12 1NY, UK
| |
Collapse
|
4
|
Morrow E, Lannigan A, Doughty J, Litherland J, Mansell J, Stallard S, Mallon E, Romics L. Population-based study of the sensitivity of axillary ultrasound imaging in the preoperative staging of node-positive invasive lobular carcinoma of the breast. Br J Surg 2018; 105:987-995. [PMID: 29623677 DOI: 10.1002/bjs.10791] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2017] [Revised: 08/12/2017] [Accepted: 11/12/2017] [Indexed: 01/13/2023]
Abstract
BACKGROUND Preoperative staging of the axilla is important to allow decisions regarding neoadjuvant treatment and the management of the axilla. Invasive lobular carcinoma metastases are difficult to detect because of the infiltrative pattern of the nodal spread. In this study the sensitivity of preoperative axillary staging between invasive lobular (ILC) and ductal (IDC) carcinoma was compared. METHODS All women diagnosed with pure ILC or IDC in the West of Scotland in 2012-2014 were identified from a database maintained prospectively within the Managed Clinical Network. Pretreatment axillary ultrasound imaging (AUS), core biopsy and fine-needle aspiration cytology (FNAC) results were compared between ILC and IDC. RESULTS Some 602 women with ILC and 4199 with IDC had undergone axillary surgery, of whom 209 and 1402 respectively had nodal metastases. Pretreatment AUS sensitivity was significantly lower in ILC than in IDC (32·1 versus 50·1 per cent respectively, P < 0·001; OR 0·47, 95 per cent c.i. 0·34 to 0·64). Core biopsy had equally high sensitivity of 86 per cent in both subtypes; however, FNAC was significantly less sensitive in both ILC (55 per cent; P = 0·003) and IDC (75·6 per cent; P = 0·006). Multivariable analysis revealed that cT3-4 status and symptomatic presentation were both significant in predicting nodal metastasis in patients with ILC and false-negative AUS findings (OR 3·77, 95 per cent c.i. 1·69 to 8·42, P = 0·001; and OR 1·92, 1·24 to 2·98, P = 0·003, respectively). CONCLUSION AUS is inferior in detecting axillary node metastasis in ILC compared with IDC. Women with cT3-4 lobular carcinoma may benefit from ultrasound-guided axillary biopsy regardless of the ultrasonographic appearance of the nodes.
Collapse
Affiliation(s)
- E Morrow
- Department of Academic Surgery, University of Glasgow, Glasgow, UK
| | - A Lannigan
- Department of Surgery, Wishaw General Hospital, Wishaw, UK
| | - J Doughty
- Department of Surgery, Gartnavel General Hospital, Glasgow, UK
| | - J Litherland
- Department of Radiology, West of Scotland Breast Screening Centre, Glasgow, UK
| | - J Mansell
- Department of Surgery, Wishaw General Hospital, Wishaw, UK
| | - S Stallard
- Department of Surgery, Gartnavel General Hospital, Glasgow, UK
| | - E Mallon
- Department of Pathology, Queen Elizabeth University Hospital, Glasgow, UK
| | - L Romics
- Department of Academic Surgery, University of Glasgow, Glasgow, UK.,Department of Surgery, New Victoria Hospital, Glasgow, UK
| |
Collapse
|
5
|
Bartlett JMS, Bayani J, Kornaga E, Piper T, Mallon E, Yao CQ, Boutros PC, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, Seynaeve C, Can de Velde CJH, Rea DW. Abstract P1-06-02: Comparative survival analysis of multiparametric tests in the TEAM pathology study: What to do when molecular tests disagree? Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-06-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Multiparametric assays for risk are increasingly used in the management of node-negative and node-positive hormone receptor-positive invasive breast cancer. Data from multiple sources suggests different tests may provide different risk estimates at the individual patient level1. Analysis from the TEAM pathology study (Bayani and Yao et al npjBreast Cancer, 2017) allows direct comparison of prognostic information from gene signatures in a clinical trial cohort of postmenopausal patients. Risk classifications using genes comprising the following multi-parametric tests: OncotypeDx® (Genomic Health Inc.)2,3, Prosigna™(NanoString Technologies, Inc.)4-6, Mammaprint® (Agendia Inc.)7,8 were performed. For the OncotypeDX-Like Recurrence Score (RS), RNA abundance was processed to fit the measurement range as described2,3, with classification into high, intermediate or low risk groups based the derived RS and modeled for DRFS. For the Prosigna-Like Risk of Recurrence Score (ROR), samples were processed as previously outlined9, then modelled against DRFS. For the MammaPrint-Like Risk Score, samples were processed by published methods8 and modelled for DRFS. Comparing OncotypeDx-Like with Prosigna-Like showed that 45% of cases were classified identically by both (3.3% low risk, 20.9% intermediate, 20.7% high). Of 3370 cases, 353 (10.5%) had scores differing by more than 1 classification (i.e. hi/low or low/high). Almost all (343) of these were cases classified high risk by OncotypeDX-Like RS/low risk by Prosigna-Like ROR (Table 1). Univariate Cox regression analysis, using low/low cases as a reference (relative risk of distant metastasis =1.0), suggested that cases called low risk by Prosigna-Like ROR/High risk by OncotypeDx-Like RS did not perform differently from cases called low risk by both tests (Table 2). However, all cases called intermediate by one test and high risk by another appeared to be high risk (Table 2). Comparisons between Prosigna-Like ROR and MammaPrint-Like scores showed similar concordance between low/low and high/high (52.5% of cases with concordant results). In Prosigna-Like ROR intermediate risk cases, MammaPrint-Like results divided cases between low and high risk, as predicted. Comparisons between these tests is challenging, and evidence on their discordance in risk stratification presents further dilemmas. Preliminary analysis of TEAM suggests a complex inter-relationship between test results in the same patient cohorts requiring careful evaluation.
Table 1OncotypeDX-Like RSLowInt.HighTotalLow1126163431071Prosigna-Like RORInt.1677046151486High10106697813Total289142616553370
Table 2OncotypeDX-Like RSLowInt.HighLowRef1.26 (0.57-2.79)1.13 (0.49-2.62)Prosigna-Like RORInt.1.2 (0.47-3.05)2.22 (1.03-4.78)4.27 (2.01-9.08)High6.10 (1.58-23.6)4.15 (1.79-9.59)4.92 (2.32-10.42)
Citation Format: Bartlett JMS, Bayani J, Kornaga E, Piper T, Mallon E, Yao CQ, Boutros PC, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, Seynaeve C, Can de Velde CJH, Rea DW. Comparative survival analysis of multiparametric tests in the TEAM pathology study: What to do when molecular tests disagree? [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-06-02.
Collapse
Affiliation(s)
- JMS Bartlett
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Tom Baker Cancer Centre Translational Laboratories, Calgary, AB, Canada; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - J Bayani
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Tom Baker Cancer Centre Translational Laboratories, Calgary, AB, Canada; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - E Kornaga
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Tom Baker Cancer Centre Translational Laboratories, Calgary, AB, Canada; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - T Piper
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Tom Baker Cancer Centre Translational Laboratories, Calgary, AB, Canada; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - E Mallon
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Tom Baker Cancer Centre Translational Laboratories, Calgary, AB, Canada; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - CQ Yao
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Tom Baker Cancer Centre Translational Laboratories, Calgary, AB, Canada; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - PC Boutros
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Tom Baker Cancer Centre Translational Laboratories, Calgary, AB, Canada; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - A Hasenburg
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Tom Baker Cancer Centre Translational Laboratories, Calgary, AB, Canada; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - DG Kieback
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Tom Baker Cancer Centre Translational Laboratories, Calgary, AB, Canada; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - C Markopoulos
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Tom Baker Cancer Centre Translational Laboratories, Calgary, AB, Canada; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - L Dirix
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Tom Baker Cancer Centre Translational Laboratories, Calgary, AB, Canada; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - C Seynaeve
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Tom Baker Cancer Centre Translational Laboratories, Calgary, AB, Canada; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - CJH Can de Velde
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Tom Baker Cancer Centre Translational Laboratories, Calgary, AB, Canada; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - DW Rea
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Tom Baker Cancer Centre Translational Laboratories, Calgary, AB, Canada; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| |
Collapse
|
6
|
Bartlett JMS, Thomas J, Mallon E, Piper T, Bayani J, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, Seynaeve C, van de Velde CJH, Rea DW. Abstract P1-06-04: Simplified histological grading of breast carcinoma – potential for improved concordance and consistency in breast cancer grading? Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-06-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Histological grade remains an independent predictor of outcome for invasive breast cancer. The internationally accepted standard grading system is the Elston and Ellis grading system based on a local hospital (Nottingham) cohort treated between 1951-1973. Histological grade, with nodal status, tumour size and receptor measurements (ER, PgR, HER2) give important information even in the context of current molecular testing for breast cancer. In 2009 we proposed a simplified approach to the EE system based on evidence from another hospital series (Thomas et al Histopathology 2009 DOI 10.1111/j.1365-2559.2009.03429.x). Here we report a second validation of this approach using a large phase III clinical trial cohort the Tamoxifen Exemestane Adjuvant multicentre Trial.
A single pathologist (EM) regraded over 4200 cases using a single H&E slide from the TEAM pathology study. Individual scores (1-3) were provided for tubule formation, nuclear pleomorphism and mitotic count and summed to provide the EE score (3-9) resulting in a final grade of 1, 2 or 3 for each case. As previously reported the Simplified Binary Scoring system (SBS) reorganizes this data such that each component is given a score of 1 or 2 with a sum ranging from 3-6. In the current analysis we compared the impact of this revised grading system on patient outcome.
Of 4264 centrally regraded tumours in the TEAM pathology cohort, EE scores for tubular formation were 1 in 102 cases (2.4%), 2 in 503 cases (11.8%) and 3 in 3659 (85.8%). For nuclear pleomorphism only 2 cases were EE score 1 (0.05%), 3117 were score 2 (73.1%) and 1146 score 3 (26.9%). For Mitotic count 3423 (80.3%) were scored 1, 707 (16.6%) scored 2 and 134 scored 3 using the EE system. As previously observed, most/all EE categories could be captured using a simple binary system (SBS, see Table 1).
Table 1 EE Grade SBS SCORE12335460043239705068217600618 GG Score EE GradeLowHigh 13327819.02%21377132248.98%35751790.07% GG Score SBS SCORELowHigh 33508419.35%4120284741.34%515947474.88%65751289.98%
In a comparison between conventional grading and molecular (using a Genomic-Grade signature) we observed the predicted equal split of EE Grade 2 cases into GG high/versus low. For the SBS score the higher scores were enriched for GG High cases.
We show a novel grading system can provides a potentially simple and more reproducible approach to immunohistochemical grading. Comparisons with molecular grading approaches may suggest improved concordance between novel grading approaches and molecular systems. Further comparisons with outcome and molecular signatures will be presented.
Citation Format: Bartlett JMS, Thomas J, Mallon E, Piper T, Bayani J, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, Seynaeve C, van de Velde CJH, Rea DW. Simplified histological grading of breast carcinoma – potential for improved concordance and consistency in breast cancer grading? [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-06-04.
Collapse
Affiliation(s)
- JMS Bartlett
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Western General Hospital, Edinburgh, United Kingdom; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - J Thomas
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Western General Hospital, Edinburgh, United Kingdom; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - E Mallon
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Western General Hospital, Edinburgh, United Kingdom; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - T Piper
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Western General Hospital, Edinburgh, United Kingdom; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - J Bayani
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Western General Hospital, Edinburgh, United Kingdom; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - A Hasenburg
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Western General Hospital, Edinburgh, United Kingdom; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - DG Kieback
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Western General Hospital, Edinburgh, United Kingdom; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - C Markopoulos
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Western General Hospital, Edinburgh, United Kingdom; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - L Dirix
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Western General Hospital, Edinburgh, United Kingdom; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - C Seynaeve
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Western General Hospital, Edinburgh, United Kingdom; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - CJH van de Velde
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Western General Hospital, Edinburgh, United Kingdom; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| | - DW Rea
- Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Western General Hospital, Edinburgh, United Kingdom; Western Infirmary, Glasgow, United Kingdom; University of Mainz, Mainz, Germany; Helios Medical Center, Schleswig, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom
| |
Collapse
|
7
|
Mansell J, Weiler-Mithoff E, Stallard S, Doughty JC, Mallon E, Romics L. Oncoplastic breast conservation surgery is oncologically safe when compared to wide local excision and mastectomy. Breast 2017; 32:179-185. [PMID: 28214785 DOI: 10.1016/j.breast.2017.02.006] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2016] [Revised: 01/30/2017] [Accepted: 02/08/2017] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Support for the oncological safety of oncoplastic breast conservation surgery (OBCS) is mostly based on evidence comparing recurrence rates after OBCS to wide local excision (WLE). However, OBCS is often indicated for larger cancers and oncological results should also be compared to patients treated with mastectomy. In this study we compared recurrence and survival following OBCS, mastectomy and WLE. METHODS Patients treated with OBCS between 2009 and 2012 were identified from a prospectively maintained database. For comparison, consecutive patients treated with WLE or mastectomy with or without immediate reconstruction (Ms ± IR) over the same time period were identified. Histological variables of patients were compared using Fisher Exact or Chi squared tests, and recurrence and survival were compared using Kaplan-Meier and Cox regression survival analysis. RESULTS 980 patients' data were analysed (OBCS: n = 104; WLE: n = 558; Ms ± IR: n = 318). Tumour size, grade, nodal status, ER, and PR expression of patients treated with OBCS were all significantly more adverse compared with patients treated with WLE (p < 0.001). These histological variables were similar in patients treated with Ms ± IR and OBCS. 5-year local recurrence rates were similar in all three groups (WLE: 3.4 per cent, OBCS: 2 per cent, Ms ± IR: 2.6 per cent; log rank = 0.973), while distant recurrence rates were higher after Ms ± IR and OBCS (Ms ± IR:13.1 per cent, OBCS:7.5 per cent, WLE:3.3 per cent; log rank: p < 0.001). CONCLUSION OBCS is oncologically safe in patients even when histological results are similar to patients treated with Ms ± IR.
Collapse
Affiliation(s)
- J Mansell
- Department of Surgery, New Victoria Hospital Glasgow, UK
| | | | - S Stallard
- Department of Surgery, Gartnavel General Hospital Glasgow, UK
| | - J C Doughty
- Department of Surgery, Gartnavel General Hospital Glasgow, UK
| | - E Mallon
- Department of Pathology, Queen Elizabeth University Hospital, UK
| | - L Romics
- Department of Surgery, New Victoria Hospital Glasgow, UK; Department of Surgery, Gartnavel General Hospital Glasgow, UK.
| |
Collapse
|
8
|
Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Ferree S, Sgroi D, Schnabel C, Baehner R, Mallon E, Dowsett M. Abstract S6-05: Comprehensive comparison of prognostic signatures for breast cancer in TransATAC. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-s6-05] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A number of prognostic signatures have been developed for the prediction of breast cancer recurrence in the past decade. We have developed two signatures (Clinical Treatment Score (CTS), four immunohistochemical markers (IHC4)) and validated four prognostic signatures (Oncotype Dx Recurrence Score (RS), PAM50-based Prosigna (ROR), Breast Cancer Index (BCI), and EndoPredict (EPclin)) in the TransATAC cohort. Here, we compare the prognostic performance of these six signatures for distant recurrence (DR) in years 0-10, and specifically in years 5-10 after treatment cessation.
Methods: 1231 postmenopausal women with hormone receptor positive and HER2-negative breast cancer had at least one test performed. Of these, 818 women had data on all six signatures available. IHC4, RS and BCI (linear) are molecular only signatures whereas CTS, ROR and EPclin include clinicopathological factors. The primary endpoint was DR and the primary objective was to compare the prognostic value of the six signatures in terms of DR for years 0-10, 0-5, and 5-10. Secondary objectives included the comparison of the prognostic performance for node-negative and node-positive patients separately and the additional prognostic performance of each signature to the others. Likelihood ratio statistics (LR-χ2) were used to assess the prognostic information of each signature alone or in combination with other signatures.
Results: Median follow-up for this analysis was 9.94 years (IQR 8.01-10.09) and a total of 126 DR were recorded. 818 women with HER2-negative disease for whom data of all six signatures were available were included in this analysis. For all patients, CTS and EPclin were the most prognostic signatures in years 0-10 (CTS: LR-χ2=124.9; EPclin: LR-χ2=116.2) and years 5-10 (CTS: LR-χ2=59.6; EPclin: LR-χ2=56.8) in the univariate analysis. The other four signatures performed similarly well in years 0-5, but of those only BCI and ROR provided substantial prognostic information in years 5-10 (BCI: LR-χ2=25.3; ROR: LR-χ2=43.8). In multivariate analyses comparing the added information of the molecular signatures over CTS, IHC4 and BCI provided the most information (IHC4: ΔLR-χ2=19.0; BCI: ΔLR-χ2=19.8). In node-negative patients (72.3%), the ROR showed the most prognostic value in years 0-10 (LR-χ2=48.6) and years 5-10 (LR-χ2=31.3) whereas the RS was least prognostic in this patient group. For patients with node-positive disease (27.7%), the CTS and EPclin were the most prognostic and the other four signatures provided much less prognostic information for this patient population (data not shown).
Conclusion: Overall, the CTS and EPclin were the most prognostic signatures for DR and also added significant prognostic value to the other scores in women with HER2-negative disease, primarily due to the incorporation of nodal status in these signatures. For women with node-negative disease, the ROR, BCI, and EPclin signatures provided most prognostic value whereas for those with positive nodes CTS and EPclin were most prognostic. Our analyses showed that the inclusion of clinic-pathological factors into gene signatures is highly important for deriving an accurate prognostic assessment, particularly in node-positive patients.
Citation Format: Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Ferree S, Sgroi D, Schnabel C, Baehner R, Mallon E, Dowsett M. Comprehensive comparison of prognostic signatures for breast cancer in TransATAC [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr S6-05.
Collapse
Affiliation(s)
- I Sestak
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, QMUL, London, United Kingdom; Institute of Cancer Research, London, United Kingdom; BrustZentrum Klinik St. Anna, Lucerne, Switzerland; Sividon Diagnostics, Cologne, Germany; NanoString Technologies, Seatlle, WA; Massachusetts General Hospital, Boston, MA; bioTheranostics, San Diego, CA; Genomic Health, Redwood City, CA; NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
| | - R Buus
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, QMUL, London, United Kingdom; Institute of Cancer Research, London, United Kingdom; BrustZentrum Klinik St. Anna, Lucerne, Switzerland; Sividon Diagnostics, Cologne, Germany; NanoString Technologies, Seatlle, WA; Massachusetts General Hospital, Boston, MA; bioTheranostics, San Diego, CA; Genomic Health, Redwood City, CA; NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
| | - J Cuzick
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, QMUL, London, United Kingdom; Institute of Cancer Research, London, United Kingdom; BrustZentrum Klinik St. Anna, Lucerne, Switzerland; Sividon Diagnostics, Cologne, Germany; NanoString Technologies, Seatlle, WA; Massachusetts General Hospital, Boston, MA; bioTheranostics, San Diego, CA; Genomic Health, Redwood City, CA; NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
| | - P Dubsky
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, QMUL, London, United Kingdom; Institute of Cancer Research, London, United Kingdom; BrustZentrum Klinik St. Anna, Lucerne, Switzerland; Sividon Diagnostics, Cologne, Germany; NanoString Technologies, Seatlle, WA; Massachusetts General Hospital, Boston, MA; bioTheranostics, San Diego, CA; Genomic Health, Redwood City, CA; NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
| | - R Kronenwett
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, QMUL, London, United Kingdom; Institute of Cancer Research, London, United Kingdom; BrustZentrum Klinik St. Anna, Lucerne, Switzerland; Sividon Diagnostics, Cologne, Germany; NanoString Technologies, Seatlle, WA; Massachusetts General Hospital, Boston, MA; bioTheranostics, San Diego, CA; Genomic Health, Redwood City, CA; NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
| | - S Ferree
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, QMUL, London, United Kingdom; Institute of Cancer Research, London, United Kingdom; BrustZentrum Klinik St. Anna, Lucerne, Switzerland; Sividon Diagnostics, Cologne, Germany; NanoString Technologies, Seatlle, WA; Massachusetts General Hospital, Boston, MA; bioTheranostics, San Diego, CA; Genomic Health, Redwood City, CA; NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
| | - D Sgroi
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, QMUL, London, United Kingdom; Institute of Cancer Research, London, United Kingdom; BrustZentrum Klinik St. Anna, Lucerne, Switzerland; Sividon Diagnostics, Cologne, Germany; NanoString Technologies, Seatlle, WA; Massachusetts General Hospital, Boston, MA; bioTheranostics, San Diego, CA; Genomic Health, Redwood City, CA; NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
| | - C Schnabel
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, QMUL, London, United Kingdom; Institute of Cancer Research, London, United Kingdom; BrustZentrum Klinik St. Anna, Lucerne, Switzerland; Sividon Diagnostics, Cologne, Germany; NanoString Technologies, Seatlle, WA; Massachusetts General Hospital, Boston, MA; bioTheranostics, San Diego, CA; Genomic Health, Redwood City, CA; NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
| | - R Baehner
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, QMUL, London, United Kingdom; Institute of Cancer Research, London, United Kingdom; BrustZentrum Klinik St. Anna, Lucerne, Switzerland; Sividon Diagnostics, Cologne, Germany; NanoString Technologies, Seatlle, WA; Massachusetts General Hospital, Boston, MA; bioTheranostics, San Diego, CA; Genomic Health, Redwood City, CA; NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
| | - E Mallon
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, QMUL, London, United Kingdom; Institute of Cancer Research, London, United Kingdom; BrustZentrum Klinik St. Anna, Lucerne, Switzerland; Sividon Diagnostics, Cologne, Germany; NanoString Technologies, Seatlle, WA; Massachusetts General Hospital, Boston, MA; bioTheranostics, San Diego, CA; Genomic Health, Redwood City, CA; NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
| | - M Dowsett
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, QMUL, London, United Kingdom; Institute of Cancer Research, London, United Kingdom; BrustZentrum Klinik St. Anna, Lucerne, Switzerland; Sividon Diagnostics, Cologne, Germany; NanoString Technologies, Seatlle, WA; Massachusetts General Hospital, Boston, MA; bioTheranostics, San Diego, CA; Genomic Health, Redwood City, CA; NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
| |
Collapse
|
9
|
Cheang MCU, Morden J, Gao Q, Parker J, López-Knowles E, Detre S, Hills M, Zabaglo L, Tomiczek M, Mallon E, Robertson J, Smith I, Bliss J, Dowsett M. Abstract P2-10-02: The impact of intrinsic subtypes and molecular features on aromatase inhibitor induced reduction of proliferation marker of Ki67 in primary ER+ breast cancer: A POETIC study (CRUK/07/015). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-10-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Neoadjuvant endocrine therapy (NAE) is often a good option for postmenopausal (PM) women with estrogen receptor positive (ER+) breast cancers(BC). Fall in Ki67 is widely accepted as valid for predicting favorable tumor response to NAE and improved outcome. We report our planned correlative study to investigate if intrinsic subtype impacts on Ki67 changes (ΔKi67) as measured by immunohistochemistry. We also explored the correlation of several ER+ BC relevant molecular features at baseline(B) with ΔKi67.
Patients and methods
POETIC is a phase III, randomized 2:1 study for 4486 PM patients with ER+ BC to determine whether peri-operative aromatase inhibitor (AI) followed by standard adjuvant therapy improves outcome compared with standard adjuvant therapy alone. The proliferation rate was estimated as percentage (%) of cancer cells staining for Ki67. Primary biological endpoint was defined as two-week (2wk) change in Ki67 (2wkΔKi67): ln[(2wk Ki67+0.1)/(B Ki67+0.1)]. Secondary endpoint: “responders”, was % change of Ki67 defined as (2wk Ki67 – B Ki67) *100/B Ki67. “Responder” was defined as follows: reduction <50% as poor (PR), 50-75% moderate and >75% as good responder (GR).
Human whole genome expression(GE) Illumina BeadChips were performed. Data was obtained from 137 paired samples from the treatment group(T) and 49 pairs from the control(C) group with GE data passing quality check and baseline Ki67≥5% to minimise the impact of extreme values based on proportional ΔKi67. Intrinsic subtype and risk of recurrence(ROR) groups were calculated using PAM50. GE scores from Oncotype Dx, MammaPrint, p53 mutation/wildtype(Troester 2006), ER+ early response (ERE)(Hatzis 2011), estrogen-regulated genes subtypes (Oh 2006) and markers for 23 different immune cell types(Bindea 2013) were calculated. Associations of GE scores to endpoints of response were determined by Spearman correlation and chi-square tests. Bonferroni correction was used to control error rate with p<0.0005 deemed significant.
Results
At B of the 137 paired T, 64% were Luminal A (LumA), 22% Luminal B (LumB), 9% as HER-2 enriched (HER2-E), 2% as Basal-like (BLBC) and 3% as Normal-like. Subtypes at B were associated with response, with LumA showing the biggest reduction of Ki67 (p=0.0001) and GR. All GE, except ERE, correlated significantly with 2wkΔKi67 and response: higher risk groups associated with lowest reduction rate. None of immune cell types correlated with 2wkΔKi67, except that tumors enriched with T-helper 1 cell type were associated with PR (p < 0.000001).
Comparing subtypes between time-points, 85% of LumB and 42% of HER2-E were assigned instead as LumA at 2wk regardless of response. Of the 15 ROR defined high-risk group, only 33% were assigned instead as low-risk at 2wk.
Conclusion
Both LumA and LumB are endocrine sensitive. A fall of Ki67 was observed in majority of cases. Most tumors estimated as high-risk by molecular profiling showed less response and most remained moderate or high risk of recurrence on endocrine therapy. Whether molecular profiling at 2wk after starting AI predicts for long-term outcome in PM women with ER+ better than at diagnosis will need to be determined.
Citation Format: Cheang MCU, Morden J, Gao Q, Parker J, López-Knowles E, Detre S, Hills M, Zabaglo L, Tomiczek M, Mallon E, Robertson J, Smith I, Bliss J, Dowsett M, On Behalf of the POETIC Trialists. The impact of intrinsic subtypes and molecular features on aromatase inhibitor induced reduction of proliferation marker of Ki67 in primary ER+ breast cancer: A POETIC study (CRUK/07/015) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-10-02.
Collapse
Affiliation(s)
- MCU Cheang
- Institute of Cancer Research, London, United Kingdom; University of North Carolina at Chapel Hill, Chapel Hill, NC; Royal Marsden Hospital, United Kingdom; University of Glasgow; University of Nottingham, United Kingdom
| | - J Morden
- Institute of Cancer Research, London, United Kingdom; University of North Carolina at Chapel Hill, Chapel Hill, NC; Royal Marsden Hospital, United Kingdom; University of Glasgow; University of Nottingham, United Kingdom
| | - Q Gao
- Institute of Cancer Research, London, United Kingdom; University of North Carolina at Chapel Hill, Chapel Hill, NC; Royal Marsden Hospital, United Kingdom; University of Glasgow; University of Nottingham, United Kingdom
| | - J Parker
- Institute of Cancer Research, London, United Kingdom; University of North Carolina at Chapel Hill, Chapel Hill, NC; Royal Marsden Hospital, United Kingdom; University of Glasgow; University of Nottingham, United Kingdom
| | - E López-Knowles
- Institute of Cancer Research, London, United Kingdom; University of North Carolina at Chapel Hill, Chapel Hill, NC; Royal Marsden Hospital, United Kingdom; University of Glasgow; University of Nottingham, United Kingdom
| | - S Detre
- Institute of Cancer Research, London, United Kingdom; University of North Carolina at Chapel Hill, Chapel Hill, NC; Royal Marsden Hospital, United Kingdom; University of Glasgow; University of Nottingham, United Kingdom
| | - M Hills
- Institute of Cancer Research, London, United Kingdom; University of North Carolina at Chapel Hill, Chapel Hill, NC; Royal Marsden Hospital, United Kingdom; University of Glasgow; University of Nottingham, United Kingdom
| | - L Zabaglo
- Institute of Cancer Research, London, United Kingdom; University of North Carolina at Chapel Hill, Chapel Hill, NC; Royal Marsden Hospital, United Kingdom; University of Glasgow; University of Nottingham, United Kingdom
| | - M Tomiczek
- Institute of Cancer Research, London, United Kingdom; University of North Carolina at Chapel Hill, Chapel Hill, NC; Royal Marsden Hospital, United Kingdom; University of Glasgow; University of Nottingham, United Kingdom
| | - E Mallon
- Institute of Cancer Research, London, United Kingdom; University of North Carolina at Chapel Hill, Chapel Hill, NC; Royal Marsden Hospital, United Kingdom; University of Glasgow; University of Nottingham, United Kingdom
| | - J Robertson
- Institute of Cancer Research, London, United Kingdom; University of North Carolina at Chapel Hill, Chapel Hill, NC; Royal Marsden Hospital, United Kingdom; University of Glasgow; University of Nottingham, United Kingdom
| | - I Smith
- Institute of Cancer Research, London, United Kingdom; University of North Carolina at Chapel Hill, Chapel Hill, NC; Royal Marsden Hospital, United Kingdom; University of Glasgow; University of Nottingham, United Kingdom
| | - J Bliss
- Institute of Cancer Research, London, United Kingdom; University of North Carolina at Chapel Hill, Chapel Hill, NC; Royal Marsden Hospital, United Kingdom; University of Glasgow; University of Nottingham, United Kingdom
| | - M Dowsett
- Institute of Cancer Research, London, United Kingdom; University of North Carolina at Chapel Hill, Chapel Hill, NC; Royal Marsden Hospital, United Kingdom; University of Glasgow; University of Nottingham, United Kingdom
| | | |
Collapse
|
10
|
Gao Q, López-Knowles E, Cheang MCU, Morden J, Martin LA, Sidhu K, Evans D, Martins V, Dodson A, Skene A, Holcombe C, Mallon E, Abigail E, Bliss J, Robertson J, Smith I, Dowsett M. Abstract P2-09-02: True effect of aromatase inhibitor (AI) treatment on global gene expression (expr) changes in postmenopausal ER+ breast cancer (BC) patients: A POETIC study (CRUK/07/015). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-09-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND Gene expression (expr) analyses are increasingly used for characterising the pharmacodynamic response of primary BC. This includes assessing ER+ BC's dependence on estrogen (E) by measuring gene expr changes after AI-treatment. However, differences in tissue sampling and other preanalytic procedures between samples taken at diagnosis (D) and surgery (S), may lead to systematic artifactual changes that are falsely ascribed to the intervention. To identify genes whose expr is truly affected by AI, we measured global gene expr changes from paired core-cut biopsies at D and S from patients in the POETIC presurgical window trial.
METHODS In POETIC, 4486 postmenopausal women with primary ER+ BC were randomised 2:1 to receive perioperative AI (2 weeks pre + 2 weeks post surgery, termed Tr) or no perioperative treatment (termed Con), allowing gene expr changes to be compared between Tr and Con. RNA was extracted from paired RNA-later stored core-cuts of 56 Con and 157 Tr patients and arrayed on Illumina whole genome expr BeadChips. Raw data was extracted, transformed, normalised and batch-corrected. Probes not detected (p>0.01) in >=25% of samples were discarded. Impact of AI on genes was evaluated based on difference of the expr mean changes (log2(S/D)) of the Tr and Con samples.
RESULTS In the Con group, expr of 73 genes significantly changed (FDR<5%); 70 of these changed by a similar magnitude in the Tr group, indicating their change was independent of AI therapy but would have been artifactually discovered as changed by AI in the absence on Con. The 8 genes most up-regulated in Tr were all among the 20 genes most up-regulated in Con: many were early-response or stress-associated genes. Three of the 8 most down-regulated in AI were the most down-regulated in Con: all were haemoglobin-related. Expr of some genes was changed in Con (eg MYC increase) but was unaffected in Tr. Such artifactual gene changes in Con tumors conceal true AI-induced changes that would not be detected in the absence of comparison with Con.
615 genes were down-regulated and 472 up-regulated in Tr but not Con. The majority of down-regulated genes were cell cycle or proliferation-associated or E-regulated, including ESR1, PDZK1, GREB1, HSPB1. Functional mapping showed changes in the regulation of cyclins and cyclin dependent kinases impacting on G1/S and G2/M. Of note, up-regulated genes included CDK6 (target for CDK4/6 inhibitors) and CCND2, involved in G1/S checkpoint regulation; SNAI2, TGFB3, TGFBR2, associated with tumour invasion and metastasis; and other genes involved in aryl hydrocarbon receptor, Glioblastoma Multiforme, HIPPO and p53 signalling.
CONCLUSION Expr of certain genes is altered by processes involved in presurgical window studies. In the absence of a Con group, these may be wrongly ascribed to an experimental intervention or wrongly considered as unaffected by the intervention (eg MYC in this study).
Down-regulation of E-responsive and proliferation genes was an expected response to AI but increased expr of genes such as SNAI2, CCND2 and CDK6 indicates immediate tumour re-wiring and provides mechanistic support for benefit from combination therapy with a CDK4/6 inhibitor.
Citation Format: Gao Q, López-Knowles E, Cheang MCU, Morden J, Martin L-A, Sidhu K, Evans D, Martins V, Dodson A, Skene A, Holcombe C, Mallon E, Abigail E, Bliss J, Robertson J, Smith I, Dowsett M. True effect of aromatase inhibitor (AI) treatment on global gene expression (expr) changes in postmenopausal ER+ breast cancer (BC) patients: A POETIC study (CRUK/07/015) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-09-02.
Collapse
Affiliation(s)
- Q Gao
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Liverpool University Hospital, Liverpool, United Kingdom; Queen Elizabeth University Hospital Glasgow, Govan, United Kingdom; Poole Hospital NHS Foundation Trust, Dorset, United Kingdom; University of Nottingham, Derby, United Kingdom
| | - E López-Knowles
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Liverpool University Hospital, Liverpool, United Kingdom; Queen Elizabeth University Hospital Glasgow, Govan, United Kingdom; Poole Hospital NHS Foundation Trust, Dorset, United Kingdom; University of Nottingham, Derby, United Kingdom
| | - MCU Cheang
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Liverpool University Hospital, Liverpool, United Kingdom; Queen Elizabeth University Hospital Glasgow, Govan, United Kingdom; Poole Hospital NHS Foundation Trust, Dorset, United Kingdom; University of Nottingham, Derby, United Kingdom
| | - J Morden
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Liverpool University Hospital, Liverpool, United Kingdom; Queen Elizabeth University Hospital Glasgow, Govan, United Kingdom; Poole Hospital NHS Foundation Trust, Dorset, United Kingdom; University of Nottingham, Derby, United Kingdom
| | - L-A Martin
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Liverpool University Hospital, Liverpool, United Kingdom; Queen Elizabeth University Hospital Glasgow, Govan, United Kingdom; Poole Hospital NHS Foundation Trust, Dorset, United Kingdom; University of Nottingham, Derby, United Kingdom
| | - K Sidhu
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Liverpool University Hospital, Liverpool, United Kingdom; Queen Elizabeth University Hospital Glasgow, Govan, United Kingdom; Poole Hospital NHS Foundation Trust, Dorset, United Kingdom; University of Nottingham, Derby, United Kingdom
| | - D Evans
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Liverpool University Hospital, Liverpool, United Kingdom; Queen Elizabeth University Hospital Glasgow, Govan, United Kingdom; Poole Hospital NHS Foundation Trust, Dorset, United Kingdom; University of Nottingham, Derby, United Kingdom
| | - V Martins
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Liverpool University Hospital, Liverpool, United Kingdom; Queen Elizabeth University Hospital Glasgow, Govan, United Kingdom; Poole Hospital NHS Foundation Trust, Dorset, United Kingdom; University of Nottingham, Derby, United Kingdom
| | - A Dodson
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Liverpool University Hospital, Liverpool, United Kingdom; Queen Elizabeth University Hospital Glasgow, Govan, United Kingdom; Poole Hospital NHS Foundation Trust, Dorset, United Kingdom; University of Nottingham, Derby, United Kingdom
| | - A Skene
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Liverpool University Hospital, Liverpool, United Kingdom; Queen Elizabeth University Hospital Glasgow, Govan, United Kingdom; Poole Hospital NHS Foundation Trust, Dorset, United Kingdom; University of Nottingham, Derby, United Kingdom
| | - C Holcombe
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Liverpool University Hospital, Liverpool, United Kingdom; Queen Elizabeth University Hospital Glasgow, Govan, United Kingdom; Poole Hospital NHS Foundation Trust, Dorset, United Kingdom; University of Nottingham, Derby, United Kingdom
| | - E Mallon
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Liverpool University Hospital, Liverpool, United Kingdom; Queen Elizabeth University Hospital Glasgow, Govan, United Kingdom; Poole Hospital NHS Foundation Trust, Dorset, United Kingdom; University of Nottingham, Derby, United Kingdom
| | - E Abigail
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Liverpool University Hospital, Liverpool, United Kingdom; Queen Elizabeth University Hospital Glasgow, Govan, United Kingdom; Poole Hospital NHS Foundation Trust, Dorset, United Kingdom; University of Nottingham, Derby, United Kingdom
| | - J Bliss
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Liverpool University Hospital, Liverpool, United Kingdom; Queen Elizabeth University Hospital Glasgow, Govan, United Kingdom; Poole Hospital NHS Foundation Trust, Dorset, United Kingdom; University of Nottingham, Derby, United Kingdom
| | - J Robertson
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Liverpool University Hospital, Liverpool, United Kingdom; Queen Elizabeth University Hospital Glasgow, Govan, United Kingdom; Poole Hospital NHS Foundation Trust, Dorset, United Kingdom; University of Nottingham, Derby, United Kingdom
| | - I Smith
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Liverpool University Hospital, Liverpool, United Kingdom; Queen Elizabeth University Hospital Glasgow, Govan, United Kingdom; Poole Hospital NHS Foundation Trust, Dorset, United Kingdom; University of Nottingham, Derby, United Kingdom
| | - M Dowsett
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Liverpool University Hospital, Liverpool, United Kingdom; Queen Elizabeth University Hospital Glasgow, Govan, United Kingdom; Poole Hospital NHS Foundation Trust, Dorset, United Kingdom; University of Nottingham, Derby, United Kingdom
| |
Collapse
|
11
|
Affiliation(s)
- M McCaffrey
- Department of Obstetrics and Gynaecology (RCSI), Rotunda Hospital
| | - E Cottell
- Department of Obstetrics and Gynaecology (RCSI), Rotunda Hospital
| | - D Keane
- Department of Obstetrics and Gynaecology (RCSI), Rotunda Hospital
| | - E Mallon
- Department of Obstetrics and Gynaecology (RCSI), Rotunda Hospital
| | - T Walsh
- Department of Obstetrics and Gynaecology (RCSI), Rotunda Hospital
| | - J McMorrow
- Department of Microbiology, Rotunda Hospital
| | - M Cafferkey
- Department of Microbiology, Rotunda Hospital
| | - E O'Kelly
- Department of Virology, University College, Dublin, Ireland
| | - R Harrison
- Department of Microbiology, Rotunda Hospital
| |
Collapse
|
12
|
Campbell E, Tesson M, Doogan F, Mohammed Z, Mallon E, Edwards J. The combined endocrine receptor (CER) is a better discriminator of patient outcome than ER and PR alone. Int J Surg 2016. [DOI: 10.1016/j.ijsu.2016.08.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
13
|
O'Leary B, Alarcon L, Mallon E, Kirby A. Radiotherapy-associated Pemphigus - a Rare Cause of Grade 4 Skin Toxicity. Clin Oncol (R Coll Radiol) 2016; 29:e50. [PMID: 27618424 DOI: 10.1016/j.clon.2016.08.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2016] [Accepted: 08/25/2016] [Indexed: 10/21/2022]
Affiliation(s)
- B O'Leary
- Department of Academic Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK
| | - L Alarcon
- Department of Cellular Pathology, South West London Pathology, London, UK
| | - E Mallon
- Department of Dermatology, Croydon University Hospital, London, UK
| | - A Kirby
- Department of Academic Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK
| |
Collapse
|
14
|
Ling T, Clayton T, Crawley J, Exton L, Goulden V, Ibbotson S, McKenna K, Mohd Mustapa M, Rhodes L, Sarkany R, Dawe R, McHenry P, Hughes J, Griffiths M, McDonagh A, Buckley D, Nasr I, Swale V, Duarte Williamson C, Levell N, Leslie T, Mallon E, Wakelin S, Hunasehally P, Cork M, Ungureanu S, Donnelly J, Towers K, Saunders C, Davis R, Brain A, Exton L, Mohd Mustapa M. British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen–ultraviolet A therapy 2015. Br J Dermatol 2016; 174:24-55. [DOI: 10.1111/bjd.14317] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/19/2015] [Indexed: 01/28/2023]
Affiliation(s)
- T.C. Ling
- Dermatology Centre Faculty of Medical and Human Sciences Salford Royal NHS Foundation Trust Salford Manchester M6 8HD U.K
| | - T.H. Clayton
- Dermatology Centre Faculty of Medical and Human Sciences Salford Royal NHS Foundation Trust Salford Manchester M6 8HD U.K
| | - J. Crawley
- Department of Dermatology University College Hospital 235 Euston Road London NW1 2BU U.K
| | - L.S. Exton
- British Association of Dermatologists Willan House 4 Fitzroy Square London W1T 5HQ U.K
| | - V. Goulden
- Department of Dermatology Leeds Teaching Hospitals NHS Trust Leeds LS7 4SA U.K
| | - S. Ibbotson
- Department of Dermatology Ninewells Hospital and Medical School University of Dundee Dundee DD1 9SY U.K
| | - K. McKenna
- Department of Dermatology Belfast City Hospital Belfast BT9 7AB U.K
| | - M.F. Mohd Mustapa
- British Association of Dermatologists Willan House 4 Fitzroy Square London W1T 5HQ U.K
| | - L.E. Rhodes
- Dermatology Research Centre Faculty of Medical and Human Sciences Salford Royal NHS Foundation Trust Salford Manchester M6 8HD U.K
| | - R. Sarkany
- Department of Dermatology University College Hospital 235 Euston Road London NW1 2BU U.K
| | - R.S. Dawe
- Department of Dermatology Ninewells Hospital and Medical School University of Dundee Dundee DD1 9SY U.K
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Munzone E, Giobbie-Hurder A, Gusterson BA, Mallon E, Viale G, Thürlimann B, Ejlertsen B, MacGrogan G, Bibeau F, Lelkaitis G, Price KN, Gelber RD, Coates AS, Goldhirsch A, Colleoni M. Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. Ann Oncol 2015; 26:2442-9. [PMID: 26387144 DOI: 10.1093/annonc/mdv391] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2015] [Accepted: 09/14/2015] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND We investigated the outcomes of postmenopausal women with hormone receptor-positive, early breast cancer with special histotypes (mucinous, tubular, or cribriform) enrolled in the monotherapy cohort of the BIG 1-98 trial. PATIENTS AND METHODS The intention-to-treat BIG 1-98 monotherapy cohort (5 years of therapy with tamoxifen or letrozole) included 4922 women, of whom 4091 had central pathology review. Histotype groups were defined as: mucinous (N = 100), tubular/cribriform (N = 83), ductal (N = 3257), and other (N = 651). Of 183 women with either mucinous or tubular/cribriform tumors, 96 were randomly assigned to letrozole and 87 to tamoxifen. Outcomes assessed were disease-free survival (DFS), overall survival (OS), breast cancer-free interval (BCFI), and distant recurrence-free interval (DRFI). Median follow-up in the analytic cohort was 8.1 years. RESULTS Women with tubular/cribriform breast cancer had the best outcomes for all end points compared with the other three histotypes, and had less breast cancer recurrence (97.5% 5-year BCFI) than those with mucinous (93.5%), ductal (88.9%), or other (89.9%) histotypes. Patients with mucinous or tubular/cribriform carcinoma had better DRFI (5-year rates 97.8% and 98.8%, respectively) than those with ductal (90.9%) or other (92.1%) carcinomas. Within the subgroup of women with special histotypes, we observed a nonsignificant increase in the hazard of breast cancer recurrence with letrozole [hazard (letrozole versus tamoxifen): 3.31, 95% confidence interval 0.94-11.7; P = 0.06]. CONCLUSIONS Women with mucinous or tubular/cribriform breast cancer have better outcomes than those with other histotypes, although the observation is based on a limited number of events. In postmenopausal women with these histotypes, the magnitude of the letrozole advantage compared with tamoxifen may not be as large in patients with mucinous or tubular/cribriform disease. CLINICALTRIALSGOV NCT00004205.
Collapse
Affiliation(s)
- E Munzone
- Division of Medical Senology, European Institute of Oncology, Milan, Italy
| | - A Giobbie-Hurder
- Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Boston, USA
| | - B A Gusterson
- Institute of Cancer Sciences, Glasgow University, Glasgow
| | - E Mallon
- Southern General Hospital, Glasgow, UK
| | - G Viale
- Department of Pathology and Laboratory Medicine, IBCSG Central Pathology Laboratory, European Institute of Oncology, and University of Milan, Milan, Italy
| | - B Thürlimann
- Breast Center, Kantonsspital, St Gallen Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
| | - B Ejlertsen
- Danish Breast Cancer Cooperative Group (DBCG), Rigshospitalet, Copenhagen, Denmark
| | - G MacGrogan
- Department of Pathology, Institut Bergonié, Bordeaux
| | - F Bibeau
- Department of Pathology, Val d'Aurelle Cancer Institute, Montpellier, France
| | - G Lelkaitis
- Department of Pathology, Rigshospitalet, Copenhagen, Denmark
| | - K N Price
- International Breast Cancer Study Group (IBCSG) Statistical Center
| | - R D Gelber
- Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Boston, USA Harvard T.H. Chan School of Public Health, Harvard Medical School, Frontier Science and Technology Research Foundation, Boston, USA
| | - A S Coates
- International Breast Cancer Study Group, Bern, Switzerland University of Sydney, Sydney, Australia
| | - A Goldhirsch
- Program of Breast Health, European Institute of Oncology, Milan, Italy
| | - M Colleoni
- Division of Medical Senology, European Institute of Oncology, Milan, Italy
| | | |
Collapse
|
16
|
Moseley H, Allan D, Amatiello H, Coleman A, du Peloux Menagé H, Edwards C, Exton L, Ferguson J, Garibaldinos T, Martin C, Mohd Mustapa M, McHenry P, Griffiths M, Buckley D, Nasr I, Swale V, Duarte Williamson C, Leslie T, Mallon E, Towers K, Saunders C, Brain A. Guidelines on the measurement of ultraviolet radiation levels in ultraviolet phototherapy: report issued by the British Association of Dermatologists and British Photodermatology Group 2015. Br J Dermatol 2015; 173:333-50. [DOI: 10.1111/bjd.13937] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/17/2015] [Indexed: 11/26/2022]
Affiliation(s)
- H. Moseley
- The Photobiology Unit Ninewells Hospital and Medical School Dundee DD1 9SY U.K
| | - D. Allan
- The Christie NHS Foundation Trust and University of Manchester Manchester Academic Health Science Centre Wilmslow Road Manchester M20 4BX U.K
| | - H. Amatiello
- Radiation Physics and Protection Group Churchill Hospital Old Road Headington Oxford OX3 7LJ U.K
| | - A. Coleman
- Guy's and St Thomas' NHS Foundation Trust St Thomas' Hospital Westminster Bridge Road London SE1 7EH U.K
| | - H. du Peloux Menagé
- Guy's and St Thomas' NHS Foundation Trust St Thomas' Hospital Westminster Bridge Road London SE1 7EH U.K
- Lewisham and Greenwich NHS Trust High Street London SE13 6LH U.K
| | - C. Edwards
- Royal Gwent Hospital Cardiff Road Newport NP20 2UB U.K
| | - L.S. Exton
- British Association of Dermatologists Willan House, 4 Fitzroy Square London W1T 5HQ U.K
| | - J. Ferguson
- The Photobiology Unit Ninewells Hospital and Medical School Dundee DD1 9SY U.K
| | - T. Garibaldinos
- Guy's and St Thomas' NHS Foundation Trust St Thomas' Hospital Westminster Bridge Road London SE1 7EH U.K
| | - C. Martin
- Department of Clinical Physics and Bio‐Engineering University of Glasgow Glasgow G12 8QQ U.K
| | - M.F. Mohd Mustapa
- British Association of Dermatologists Willan House, 4 Fitzroy Square London W1T 5HQ U.K
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Palmieri C, Cleator S, Kilburn LS, Kim SB, Ahn SH, Beresford M, Gong G, Mansi J, Mallon E, Reed S, Mousa K, Fallowfield L, Cheang M, Morden J, Page K, Guttery DS, Rghebi B, Primrose L, Shaw JA, Thompson AM, Bliss JM, Coombes RC. NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer. Breast Cancer Res Treat 2014; 148:581-90. [PMID: 25395314 DOI: 10.1007/s10549-014-3183-4] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2014] [Accepted: 10/24/2014] [Indexed: 01/09/2023]
Abstract
Neoadjuvant endocrine therapy is an alternative to chemotherapy for women with oestrogen receptor (ER)-positive early breast cancer (BC). We aimed to assess feasibility of recruiting patients to a study comparing chemotherapy versus endocrine therapy in postmenopausal women with ER-rich primary BC, and response as well as translational endpoints were assessed. Patients requiring neoadjuvant therapy were randomised to chemotherapy: 6 × 3-weekly cycles FE₁₀₀C or endocrine therapy: letrozole 2.5 mg, daily for 18-23 weeks. Primary endpoints were recruitment feasibility and tissue collection. Secondary endpoints included clinical, radiological and pathological response rates, quality of life and translational endpoints. 63/80 patients approached were eligible, of those 44 (70, 95% CI 57-81) were randomised. 12 (54.5, 95% CI 32.2-75.6) chemotherapy patients showed radiological objective response compared with 13 (59.1, 95% CI 36.4-79.3) letrozole patients. Compared with baseline, mean Ki-67 levels fell in both groups at days 2-4 and at surgery [fold change: 0.24 (95% CI 0.12-0.51) and 0.24; (95% CI 0.15-0.37), respectively]. Plasma total cfDNA levels rose from baseline to week 8 [fold change: chemotherapy 2.10 (95% CI 1.47-3.00), letrozole 1.47(95% CI 0.98-2.20)], and were maintained at surgery in the chemotherapy group [chemotherapy 2.63; 95% CI 1.56-4.41), letrozole 0.95 (95% CI 0.71-1.26)]. An increase in plasma let-7a miRNA was seen at surgery for patients with objective radiological response to chemotherapy. Recruitment and tissue collection endpoints were met; however, a larger trial was deemed unfeasible due to slow accrual. Both regimens were equally efficacious. Dynamic changes were seen in Ki-67 and circulating biomarkers in both groups with increases in cfDNA and let-7a miRNA persisting until surgery for chemotherapy patients.
Collapse
Affiliation(s)
- C Palmieri
- Institute of Translational Medicine, University of Liverpool, Liverpool, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Blamey RW, Bates T, Chetty U, Duffy SW, Ellis IO, George D, Mallon E, Mitchell MJ, Monypenny I, Morgan DAL, Macmillan RD, Patnick J, Pinder SE. Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer 2013; 49:2294-302. [PMID: 23523089 DOI: 10.1016/j.ejca.2013.02.031] [Citation(s) in RCA: 142] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2011] [Revised: 01/31/2013] [Accepted: 02/25/2013] [Indexed: 11/26/2022]
Abstract
BACKGROUND The incidence of local recurrence (LR) after conservative surgery for early breast cancer without adjuvant therapy is unacceptably high even with favourable tumours. The aim of this study was to examine the effect of adjuvant therapies in tumours with excellent prognostic features. METHODS Patients with primary invasive breast cancer <2 cm diameter, grade 1 or good prognosis special type, and node negative, treated by wide local excision (WLE) with clear margins were randomised into a 2 × 2 clinical trial of factorial design with or without radiotherapy and with or without tamoxifen. Trial entry was allowed to either comparison or both. FINDINGS The actuarial breast cancer specific survival in 1135 randomised patients at 10 years was 96%. Analysis by intention to treat showed that LR after WLE was reduced in patients randomised to radiotherapy (RT) (HR 0.37, CI 0.22-0.61 p<0.001) and to tamoxifen (HR 0.33, CI 0.15 - 0.70 p<0.004). Actuarial analysis of patients entered into the four-way randomisation showed that LR after WLE alone was 1.9% per annum (PA) versus 0.7% with RT alone and 0.8% with tamoxifen alone. No patient randomised to both adjuvant treatments developed LR. Analysis by treatment received showed LR at 2.2%PA for surgery alone versus 0.8% for either adjuvant radiotherapy or tamoxifen and 0.2% for both treatments. CONCLUSIONS Even in these patients with tumours of excellent prognosis, LR after conservative surgery without adjuvant therapy was still very high. This was reduced to a similar extent by either radiotherapy or tamoxifen but to a greater extent by the receipt of both treatments.
Collapse
Affiliation(s)
- R W Blamey
- Nottingham City Hospital, Hucknall Rd., Nottingham NG5 1PB, United Kingdom
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Ohotski J, Long JS, Orange C, Elsberger B, Mallon E, Doughty J, Pyne S, Pyne NJ, Edwards J. Erratum: Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor negative breast cancer. Br J Cancer 2012. [PMCID: PMC3419969 DOI: 10.1038/bjc.2012.352] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
20
|
Bennett L, Mohammed Z, Orange C, Horgan P, Doughty J, Mallon E, Edwards J. 772 High Nuclear Expression of Activated NF-kB is Associated With Increased Recurrence in Breast Cancer Patients. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71408-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
21
|
Edwards J, Tannahill C, Obondo C, Elsberger B, Mallon E, Wilson C, Doughty J. O-14 Expression and activation of Akt and NFkB in breast cancer patients. EJC Suppl 2010. [DOI: 10.1016/j.ejcsup.2010.06.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
22
|
Bartlett J, Brookes C, Robson T, van de Velde C, Billingham L, Campbell F, Quintayo M, Lyttle N, Hasenburg A, Hille E, Kieback D, Putter H, Markopoulos C, Meershoek-Klein-Kranenbarg E, Paridaens R, Seynaeve C, Mallon E, Rea D. The TEAM Trial Pathology Study Identifies Potential Prognostic and Predictive Biomarker Models for Postmenopausal Patients Treated with Endocrine Therapy. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-75] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial included prospectively planned biomarker studies to identify prognostic and predictive biomarkers for patients receiving endocrine therapy. Quantitative IHC data for ER/PgR (Can Res 69:83S, SABCS2008), HER2, HER3 and Ki67 was available for the current analysis relative to outcome of estrogen receptor–positive (ER+) early postmenopausal breast cancer (BC) patients treated with exemestane versus tamoxifen.Patients & Methods: Pathology blocks from 4598 TEAM patients were collected and tissue microarrays constructed. Quantitative analysis of hormone receptors (HER2/3) by conventional IHC, and image analysis derived continuous scores for Ki67/ER/PgR were analyzed relative to disease-free survival and treatment on an intent to treat basis using survival data for the first 2.75 years of the TEAM trial. Data on HER2FISH and EGF Receptor IHC will be presented.Results: Of 4595 eligible cases samples received, 16 were excluded, 271 had incomplete biomarker data, leaving 4308 patients for the final biomarker analysis. 1275 (30%) cases were HER2/3 positive.A significant treatment by marker effect was observed for exemestane versus tamoxifen with HER2/3 negative cases deriving benefit from aromatase inhibitor treatment (HER2/3-ve HR=0.69 95%CI, 0.53-0.88; HER2/3 pos HR, 1.13; 95%CI, 0.82–1.55; p=0.016 for interaction in multivariate analysis). By conventional and STEPP analysis no predictive effect of Ki67 was observed. In multivariate regression analysis increased HER2 expression (P=0.0001) decreased PgR expression (P<0.0001) and increased percentage of Ki67 positive cells (P=0.004) as continuous IHC variables were independently prognostic as were size (P=0.0001), nodal status (P<0.0001), grade (P=0.03) and age (P<0.0001).Conclusion: Multiple biological parameters (HER2/PgR/Ki67) are independently prognostic in ER+ve early postmenopausal BC. Modelling will be explored to derive prognostic and potentially predictive biomarker signatures for application in BC. Preferential exemestane versus tamoxifen treatment benefit was seen in HER2/3 negative cases, whilst HER2/3 positive cases had a poor prognosis in this population receiving hormonal therapy (suggesting resistance to endocrine therapy), and no evidence of benefit from AIs versus tamoxifen. Type I receptor tyrosine kinases may identify breast cancers with relative resistance to all forms of endocrine therapy. Whilst Ki67 alone was not predictive of benefit from Ais, Ki67, HER2 and PgR were independent prognostic variables and modelling of predictive/prognostic effects may further inform treatment selection in early postmenopausal breast cancer.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 75.
Collapse
Affiliation(s)
| | - C. Brookes
- 2University of Birmingham, United Kingdom
| | - T. Robson
- 1University of Edinburgh, United Kingdom
| | | | | | | | | | - N. Lyttle
- 1University of Edinburgh, United Kingdom
| | | | - E. Hille
- 3Leiden University Medical Centre, The Netherlands
| | | | - H. Putter
- 3Leiden University Medical Centre, The Netherlands
| | | | | | | | - C. Seynaeve
- 9Erasmus MC-Daniel-den Hoed Cancer Centre, The Netherlands
| | - E. Mallon
- 7Western Infirmary Glasgow, United Kingdom
| | - D. Rea
- 2University of Birmingham, United Kingdom
| |
Collapse
|
23
|
Tovey S, Edwards J, Brown S, Mallon E, Doughty J. Poor Survival Outcomes in Elderly HER2 Positive Breast Cancer Patients. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-2010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
IntroductionIncreasing age is a major risk factor for breast cancer. The majority of breast cancers in Europe and USA are in women over 65 and with an aging population this will become an increasing concern. Despite this, there are suggestions of bias in allocating treatment based on chronological rather than physiological age, with adverse effects on survival (1). In addition, women over 70 are usually excluded from randomised clinical trials. One particular area of controversy is the treatment of HER2 positive elderly women with trastuzumab +/- concurrent chemotherapy, particularly with the concerns over cardiac toxicity in these patients.MethodsWe analysed a cohort of 255 patients older than 70 years to assess the impact of HER2 positivity (IHC Herceptest 3+ or FISH positive) on survival in elderly women with breast cancer. These patients were selected from a database of 1400 breast cancers diagnosed between 1980-2002 which contains all clinicopathological details and full follow-up (median 5.3yrs). The group were 81% ER positive, 74% grade I or II, and 49% node positive. Only 2.7% received chemotherapy but 82% received endocrine therapy (tamoxifen).SPSS version 12 was used to calculate univariate Kaplan Meier Survival Curves and multivariate cox regression analysis using breast cancer specific death as an endpoint.ResultsThe HER2 positivity rate was 5.9% which is substantially lower than the 11.9% positive in the original unselected database of 1400 patients.HER2 positive elderly patients (n=15) had significantly poorer breast cancer specific survival rates of 65% compared to 79% at 5 years for the HER2 negative group (p=0.036). In cox regression analysis along side known prognostic variables of grade, size, nodal and ER status the hazard ratio for HER2 positivity was 2.58 (95% CI 1.079-6.147, p<0.033).ConclusionAs previously reported, our cohort of elderly women have low rates of HER2 positive disease, however HER2 status remains a significant predictor of breast cancer specific survival outcome. Whilst no adjuvant trastuzumab trials have directly targeted this age group (with minimal inclusion of patients >70 in any trial), we know that cardiac toxicity increases with age and with anthracycline use (2). This however is generally reversible and treatment certainly should be considered if there is adequate cardiac function. A clinical trial to assess the benefit of adjuvant trastuzumab alone (with endocrine therapy) in this group of patients is suggested in this largely ER positive cohort. The role of the dual inhibitor lapatinib should also be explored with suggestions of less cardiotoxicity with this agent (2).Reference List1. Eaker S, Dickman PW, Bergkvist L, Holmberg L 2006 Differences in management of older women influence breast cancer survival: results from a population-based database in Sweden. PLoS Med 3:e252. Perez EA 2008 Cardiac toxicity of ErbB2-targeted therapies: what do we know? Clin Breast Cancer 8 Suppl 3:S114-S120
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 2010.
Collapse
Affiliation(s)
- S. Tovey
- 1Glasgow Royal Infirmary, United Kingdom
| | - J. Edwards
- 1Glasgow Royal Infirmary, United Kingdom
| | - S. Brown
- 1Glasgow Royal Infirmary, United Kingdom
| | - E. Mallon
- 1Glasgow Royal Infirmary, United Kingdom
| | - J. Doughty
- 1Glasgow Royal Infirmary, United Kingdom
| |
Collapse
|
24
|
Viale G, Giobbie-Hurder A, Gusterson BA, Maiorano E, Mastropasqua MG, Sonzogni A, Mallon E, Colleoni M, Castiglione-Gertsch M, Regan MM, Price KN, Brown RW, Golouh R, Crivellari D, Karlsson P, Öhlschlegel C, Gelber RD, Goldhirsch A, Coates AS. Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. Ann Oncol 2009; 21:245-254. [PMID: 19633051 DOI: 10.1093/annonc/mdp317] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Peritumoral vascular invasion (PVI) may assist in assigning optimal adjuvant systemic therapy for women with early breast cancer. PATIENTS AND METHODS Patients participated in two International Breast Cancer Study Group randomized trials testing chemoendocrine adjuvant therapies in premenopausal (trial VIII) or postmenopausal (trial IX) node-negative breast cancer. PVI was assessed by institutional pathologists and/or central review on hematoxylin-eosin-stained slides in 99% of patients (analysis cohort 2754 patients, median follow-up >9 years). RESULTS PVI, present in 23% of the tumors, was associated with higher grade tumors and larger tumor size (trial IX only). Presence of PVI increased locoregional and distant recurrence and was significantly associated with poorer disease-free survival. The adverse prognostic impact of PVI in trial VIII was limited to premenopausal patients with endocrine-responsive tumors randomized to therapies not containing goserelin, and conversely the beneficial effect of goserelin was limited to patients whose tumors showed PVI. In trial IX, all patients received tamoxifen: the adverse prognostic impact of PVI was limited to patients with receptor-negative tumors regardless of chemotherapy. CONCLUSION Adequate endocrine adjuvant therapy appears to abrogate the adverse impact of PVI in node-negative disease, while PVI may identify patients who will benefit particularly from adjuvant therapy.
Collapse
Affiliation(s)
- G Viale
- Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy.
| | - A Giobbie-Hurder
- International Breast Cancer Study Group, Statistical Center, Dana-Farber Cancer Institute, Boston, MA, USA
| | - B A Gusterson
- Division of Cancer Sciences and Molecular Pathology, Faculty of Medicine, University of Glasgow, Glasgow, UK
| | - E Maiorano
- Department of Pathological Anatomy, University of Bari, Bari, Italy
| | - M G Mastropasqua
- Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
| | - A Sonzogni
- Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
| | - E Mallon
- Division of Cancer Sciences and Molecular Pathology, Faculty of Medicine, University of Glasgow, Glasgow, UK
| | - M Colleoni
- Department of Medicine, Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy
| | | | - M M Regan
- International Breast Cancer Study Group, Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA, USA
| | - K N Price
- International Breast Cancer Study Group, Statistical Center, Frontier Science and Technology Research Foundation, Boston, MA, USA
| | - R W Brown
- Melbourne Pathology, Collingwood, Victoria, Australia
| | - R Golouh
- Department of Pathology, Institute of Oncology, Ljubljana, Slovenia
| | - D Crivellari
- Department of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy
| | - P Karlsson
- Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - C Öhlschlegel
- Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
| | - R D Gelber
- International Breast Cancer Study Group, Statistical Center, Dana-Farber Cancer Institute, Frontier Science and Technology Research Foundation, Harvard School of Public Health, Boston, MA, USA
| | - A Goldhirsch
- European Institute of Oncology, Milan, Italy; Department of Medicine, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - A S Coates
- Scientific Committee, International Breast Cancer Study Group, Bern, Switzerland; School of Public Health, University of Sydney, Sydney, Australia
| |
Collapse
|
25
|
|
26
|
Marla S, Roxburgh P, Burton P, Stallard S, Mallon E, Canney P, Cooke T. HER2 positive early breast cancers: tumour demographics and trastuzumab therapy in the real-world. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-3159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #3159
Background: Various trials have shown substantial benefits of addition of Trastuzumab (Herceptin®) to adjuvant chemotherapy in Early Breast Cancer (EBC). We analysed our breast cancer population to determine the incidence of HER2 positive Early Breast Cancers, the tumour demographics and the number of patients eligible for and receiving trastuzumab therapy in this group.
 Methods: Data for all patients diagnosed with EBC in 2006 was recorded prospectively in a database. Case notes were consulted where the HER2 positive patients, determined by a combination of IHC and FISH, had not received trastuzumab, to ascertain the reasons.
 Results: A total of 951 patients were diagnosed with Breast Cancer in 2006. 417 (43.9%) of these were screen-detected cancers.
 There were 123 (12.9%) HER2 positive newly diagnosed Breast Cancers of whom 117 were EBCs. The HER2 positivity rate in the screen detected cancers (n=417) was 9% and 17% in the symptomatic cancers (n=433).
 1. Demographics of the HER2 positive Early Breast Cancer Population:
 The median age at diagnosis was 61 yrs (range: 30-92).
 
 2. Fifty nine (50.4%) of the HER2 positive EBCs received trastuzumab therapy.
 
 Conclusions: The HER2 positivity rate is lower than that previously reported suggestive of changing demographics secondary to a high screen detected cancer population. A third of the HER2 positive tumours are screen detected. The percentage of ER positive, node negative and low grade tumours was higher than anticipated.
 Only 50% of HER 2 positive EBC patients received trastuzumab therapy. Of those who did not receive trastuzumab, the commonest reason was low risk status or age and co-morbidities precluded chemotherapy.
 HER 2 positivity alone confers high risk irrespective of pathological stage. Further trials are required to evaluate whether the substantial number of patients who are at present not eligible for trastuzumab therapy might also benefit.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3159.
Collapse
Affiliation(s)
- S Marla
- 1 Department of Surgery, Glasgow Royal Infirmary, Glasgow, United Kingdom
| | - P Roxburgh
- 2 Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
| | - P Burton
- 1 Department of Surgery, Glasgow Royal Infirmary, Glasgow, United Kingdom
| | - S Stallard
- 4 Surgery, Victoria Infirmary, Glasgow, United Kingdom
| | - E Mallon
- 3 Pathology, Western Infirmary, Glasgow, United Kingdom
| | - P Canney
- 2 Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
| | - T Cooke
- 1 Department of Surgery, Glasgow Royal Infirmary, Glasgow, United Kingdom
| |
Collapse
|
27
|
Tovey SM, Tan BA, Campbell J, Elsberger B, Brunton V, Mallon E, Cooke TC, Edwards J. Activated c-Src (Y215) kinase expression predicts for early relapse on tamoxifen in human breast cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-3025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #3025
Recent studies have demonstrated activation of the non-receptor tyrosine kinase c-Src in tamoxifen resistant breast cancer cell lines, which when treated with Src inhibitors demonstrate a reduction in motility and invasiveness. However, there are little published translational studies confirming a role for c-Src in tamoxifen resistance in vivo. We aim to determine if activated c-Src expression correlates clinically with increased recurrence on tamoxifen.
 Methods
 Tissue microarrays were constructed from a patient cohort of 402 Tamoxifen treated ER positive patients. Immunohistochemistry was performed using commercially available antibodies to Total Src as well as to activated (phosphorylated) c-Src at 2 sites (Y416 and Y215) (pSrc416 and pSrc215 respectively). Expression was assessed by 2 independent scorers (weighted histoscore method). HER1-3 status and expression of membranous phosphorylated ER (sites serine 118 and 167) had previously been determined. All statistical calculations were performed using SPSS 15, including Kaplan-Meier life table analysis with log rank testing of differences in breast cancer related relapse whilst on tamoxifen.
 Results
 Membranous pSrc215 was observed in 20.3% of the cases but was more frequently observed in the cytoplasm (85.9%) and nucleus (90.5%). Overexpression of cytoplasmic pSrc215 was associated with an earlier time to recurrence (p = 0.037).
 
 Cox regression analysis confirmed this to be independent of grade, nodal and HER1-3 status (p=0.028, HR 3.17 (1.14–8.85)). Cytoplasmic pSrc215 was also strongly correlated with membranous phospho-ER, EGFR and HER3 status (Mann Whitney; p<0.001, p=0.026, p<0.001 respectively). Membranous and nuclear pSrc215 staining were not associated with time to relapse.
 Over expression of Total Src and pSrc416 did not predict for relapse.
 Discussion
 Our findings provide support to in vitro studies linking c-Src with tamoxifen resistance. The phosphorylation site pSrc215 is a putative site of activation by HER2 and PGFR resulting in up to 50 fold activation of Src in vitro. The correlations demonstrated with HER status and membranous ER lead us to speculate that this interplay between non genomic ER and Src activation may provide a mechanism for the lack of response to tamoxifen in these patients.
 Further studies are required to determine if activated pSrc215 represents activated c-Src alone or may also represent activation of other Src family members as the Y416 and Y215 sequences are highly conserved amongst the Src kinases with homologous activation sites. If confirmed, future use of novel combination therapies with Src inhibitors may have an important role in combating tamoxifen resistance.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3025.
Collapse
Affiliation(s)
- SM Tovey
- 1 Section of Surgical and Translational Research,, University Department Surgery GRI, Glasgow, United Kingdom
| | - BA Tan
- 1 Section of Surgical and Translational Research,, University Department Surgery GRI, Glasgow, United Kingdom
| | - J Campbell
- 1 Section of Surgical and Translational Research,, University Department Surgery GRI, Glasgow, United Kingdom
| | - B Elsberger
- 1 Section of Surgical and Translational Research,, University Department Surgery GRI, Glasgow, United Kingdom
| | - V Brunton
- 1 Section of Surgical and Translational Research,, University Department Surgery GRI, Glasgow, United Kingdom
| | - E Mallon
- 1 Section of Surgical and Translational Research,, University Department Surgery GRI, Glasgow, United Kingdom
| | - TC Cooke
- 1 Section of Surgical and Translational Research,, University Department Surgery GRI, Glasgow, United Kingdom
| | - J Edwards
- 1 Section of Surgical and Translational Research,, University Department Surgery GRI, Glasgow, United Kingdom
| |
Collapse
|
28
|
Tovey S, Edwards J, Brown S, Mallon E, Cooke T. Poor survival outcomes in HER2 positive breast cancer patients with low grade, node negative tumours. Eur J Surg Oncol 2008. [DOI: 10.1016/j.ejso.2008.06.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
29
|
Setterfield J, Theron J, Vaughan R, Welsh K, Mallon E, Wojnarowska F, Challacombe S, Black M. Mucous membrane pemphigoid: HLA-DQB1*0301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG production. Br J Dermatol 2008. [DOI: 10.1111/j.1365-2133.2001.04380.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
30
|
Tovey S, Edwards J, Brown S, Mallon E, Cooke T. Poor survival outcomes in HER2 positive breast cancer patients with low grade, node negative tumours. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)71578-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
31
|
Forder A, Romics L, Ogston K, Stallard S, Cooke T, Mallon E, Weiller-Mithoff E. The oncological safety of axillary node clearance in the lateral decubitus position in patients with immediate ALD reconstructions. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)70853-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
32
|
Blamey R, Chetty U, Bates T, Duffy S, Ellis I, George D, Mallon E, Mitchell M, Morgan D, Macmillan R, Patnick J, Pinder S. O-11 Radiotherapy and/or tamoxifen after conserving surgery for breast cancers of excellent prognosis: BASO II TRIAL. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71701-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
33
|
Leroux K, Mallon E, Ayliffe WH. Chronic granulomatous disease and peripheral ulcerative keratitis: a rare case of recurrent external ocular disease. Bull Soc Belge Ophtalmol 2004:47-53. [PMID: 15510722] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
CLINICAL REPORT We report a case of a 29-year-old lady, with known Chronic Granulomatous Disease, who presented with an acneiform scarring facial and trunk eruption and sore red eyes. Slitlamp examination showed limbal granulomas and adjacent peripheral ulcerative keratitis. DISCUSSION The authors are considering the possible causes of the keratitis. As there were no signs of blepharitis at the time of initial presentation, the keratitis was most likely mediated by the adjacent limbal granuloma, and not due to Staphylococcal hypersensitivity. CONCLUSION Although ocular involvement in CGD has been described before, this is the first article that describes limbal granulomata and peripheral ulcerative keratitis. Multidisciplinary management with longstanding oral antibiotic treatment, and topical combined antibiotic-steroid treatment were required to bring the condition under control.
Collapse
Affiliation(s)
- K Leroux
- Department of Ophthalmology, Mayday University Hospital, London, UK.
| | | | | |
Collapse
|
34
|
Dowsett M, Bartlett J, Ellis IO, Salter J, Hills M, Mallon E, Watters AD, Cooke T, Paish C, Wencyk PM, Pinder SE. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003; 199:418-23. [PMID: 12635131 DOI: 10.1002/path.1313] [Citation(s) in RCA: 188] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Accurate diagnostic assessment of HER-2 is essential for the appropriate application of the humanized anti-HER-2 monoclonal antibody trastuzumab (Herceptin) to the treatment of patients with metastatic breast cancer. The diagnostic test needs to be applicable to archival, fixed tissue removed at excision, in many cases several years earlier. We compared the assessment of HER-2 by immunohistochemistry (IHC; HercepTest) and fluorescence in situ hybridization (FISH) in 426 breast carcinomas from patients being considered for trastuzumab therapy. The tumours were tested in three reference centres having been sent in from 37 hospitals. Only 2/270 (0.7%) IHC 0/1+ tumours were FISH positive. Six of 102 (5.9%) IHC 3+ tumours were FISH negative. Five of the six had between 1.75 and 2.0 HER-2 gene copies per chromosome 17 and the sixth had multiple copies of chromosome 17. Thirteen per cent of tumours were IHC 2+ and overall 48% of these were FISH positive but this proportion varied markedly between the centres. Sixty IHC-stained slides selected to be enriched with 2+ cases were circulated between the three laboratories and scored. There were 20 cases in which there was some discordance in scoring. Consideration of the FISH score in these cases led to concordance in the designation of positivity/negativity in 19 of these 20 cases. These data support an algorithm in which FISH testing is restricted to IHC 2+ tumours in reference centres. The results may not extrapolate to laboratories with less experience or using different methodologies.
Collapse
Affiliation(s)
- M Dowsett
- Academic Department of Biochemistry, Royal Marsden NHS Trust, London, UK.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Setterfield J, Theron J, Vaughan RW, Welsh KI, Mallon E, Wojnarowska F, Challacombe SJ, Black MM. Mucous membrane pemphigoid: HLA-DQB1*0301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG production. Br J Dermatol 2001; 145:406-14. [PMID: 11531829 DOI: 10.1046/j.1365-2133.2001.04380.x] [Citation(s) in RCA: 77] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND Class I human leucocyte antigens (HLA) -A, -B, -Cw and class II HLA-DRB1, -DQB1 alleles were determined in 131 British Caucasian patients with mucous membrane pemphigoid (MMP) using serological and DNA-based methods. OBJECTIVES To analyse the class I and II alleles expressed in well-defined clinical and immunopathological subgroups of MMP, in order to establish whether specific alleles or haplotypes might in part explain disease susceptibility, clinical sites of involvement or disease severity. METHODS Subgroups of patients were analysed according to the following clinical criteria: age of onset, sex, sites of clinical involvement (oral, ocular, skin, nasal, genital, pharyngeal, oesophageal, laryngeal, perianal), disease severity and history of autoimmune disease. Subgroups were also analysed according to the following immunopathological criteria: autoantibody profile, the presence of circulating antibasement membrane IgG or IgA antibodies and the detection of target basement membrane zone (BMZ) antigens (BP230 and BP180) by IgG autoantibodies. RESULTS Class I HLA typing showed no significant disease or subgroup associations. Class II DRB1 typing showed a significantly increased allelic frequency in MMP vs. controls for DRB1*11 (RR = 2.08, Pc < 0.0000056). For DQB1, MMP vs. controls, there was a significantly increased allelic frequency for DQB1*0301 (Pc < 0.00000028) in both males and females; all clinical sites of involvement, with the exception of laryngeal, oesophageal and perianal sites and in patients with detectable circulating anti-BMZ IgG compared with those negative for IgG (P < 0.0096, Pc < 0.019). A positive trend was noted in patients with ocular involvement compared with no ocular involvement and in patients with a clinical score > or = 10 compared with < 10. We found no difference in DQB1*0301 allele frequency between subgroups with or without BP180 or BP230 target antigens. Haplotype frequencies showed an increase in DRB1*04, DQB1*0301 (Pc < 0.000066) and DRB1*11, DQB1*0301 (Pc < 0.000002) among patients compared with controls. CONCLUSIONS The DQB1*0301 allele confers a predisposition to all subgroups of MMP and may have a role in T-cell recognition of basement membrane antigens, resulting in the production of anti-BMZ IgG autoantibodies. The positive trend between increased allelic expression of DQB1*0301 in patients with ocular disease and in those with a higher clinical score, further suggests a role for this allele in disease severity.
Collapse
Affiliation(s)
- J Setterfield
- St John's Institute of Dermatology (GKT), St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK.
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Davison SC, Allen MH, Mallon E, Barker JN. Contrasting patterns of streptococcal superantigen-induced T-cell proliferation in guttate vs. chronic plaque psoriasis. Br J Dermatol 2001; 145:245-51. [PMID: 11531786 DOI: 10.1046/j.1365-2133.2001.04341.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
BACKGROUND Streptococcal infection is strongly associated with guttate psoriasis (GP) and may also exacerbate chronic plaque psoriasis (CPP), possibly through the release of superantigenic toxins. OBJECTIVES To investigate superantigen-induced generation of cutaneous lymphocyte associated antigen (CLA) -positive lymphocytes in GP compared with CPP. METHODS Peripheral blood lymphocyte (PBL) expression of CLA and T-cell receptor Vbeta chain was assessed in patients with CPP and with active and resolved GP. Expression of superantigen-reactive Vbeta families was compared with in vitro superantigen-induced peripheral blood mononuclear cell (PBMC) proliferation. RESULTS Peripheral blood mononuclear cells from patients with active GP showed a twofold increased proliferation after stimulation with streptococcal pyogenic toxins A and streptococcal pyogenic toxins C compared with controls (P < 0.01), whereas the response to the staphylococcal toxins and mitogenic stimulation was the same in all groups. Peripheral blood lymphocytes (PBL) from patients with active GP showed increased use of the superantigen-reactive families Vbeta2 (P < 0.01) and Vbeta17 (P < 0.05), which was not evident in the other patient groups or controls. This pattern of Vbeta expression was only observed in CLA-positive T cells. Furthermore, there was a positive correlation between Vbeta2 expression and enhanced proliferation after stimulation with SPEA (r = 0.82, P < 0.01) and SPEC (r = 0.74, P < 0.05) in active GP. CONCLUSIONS This study supports the concept that streptococcal infection precipitates acute GP at least in part through superantigen driven generation of Vbeta-restricted CLA-positive skin homing lymphocytes, whereas we could find no evidence for a similar mechanism occurring in the maintenance of stable CPP.
Collapse
Affiliation(s)
- S C Davison
- St John's Institute of Dermatology, King's College London, UK
| | | | | | | |
Collapse
|
37
|
Harrison RF, Jacob S, Spillane H, Mallon E, Hennelly B. A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-beta) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertil Steril 2001; 75:23-31. [PMID: 11163812 DOI: 10.1016/s0015-0282(00)01643-5] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
OBJECTIVE Comparison of the efficacy of differing starter doses of recombinant follicle stimulating hormone (rFSH) for IVF and intracytoplasmic sperm injection cycles when the treatment is administered both subcutaneously and intramuscularly. DESIGN Single center 1-year prospective randomized study. SETTING Academic teaching hospital. PATIENT(S) 345 couples in first cycle. INTERVENTION(S) Treatment with subcutaneous or intramuscular rFSH, followed by E(2) and ultrasound follicle tracking, with later oocyte collection and zygote transfer. MAIN OUTCOME MEASURE(S) Ovarian response and other clinically dependent variables. RESULT(S) Group 1 patients, with day-3 FSH levels of less than 8.5 U/L, were randomized to begin treatment with rFSH at 150 IU (n = 146) or 200 IU (n = 151). The total dose of the drugs used was significantly lower in 150 IU group, as was the number of ICSI metaphase II oocytes. No other significant differences found. The dosage was increased in 9% on day 5. Group 2 patients, with day-3 FSH levels of greater than 8.5 U/L, were randomized to treatment with rFSH at 300 IU (n = 24) or 400 IU (n = 24). No significant outcome differences found between the two subgroups. Pregnancy rates for this group were half that of Group 1.Intramuscular administration was significantly more likely to result in a need for increased dosage than was subcutaneous administration. The level of E(2) at the time of hCG treatment was significantly lower in the intramuscular 150 IU group. CONCLUSION(S) In the main study total dosage used, the ICSI metaphase II oocyte numbers were significantly lower and there was a trend toward a need for a dosage increase on day 5 when 150 IU rFSH was the starter dosage, as compared to a starting dosage of 200 IU. Otherwise, there is little advantage to using the higher dosage.
Collapse
Affiliation(s)
- R F Harrison
- RCSI Department of Obstetrics and Gynaecology and Human Assisted Reproduction Unit, Rotunda Hospital, Dublin, Ireland
| | | | | | | | | |
Collapse
|
38
|
Abstract
Determining the HER2 status of breast carcinomas is a prerequisite for the use of the monoclonal antibody trastuzumab (Herceptin), which has recently been licensed for the treatment of metastatic disease. This necessitates a test based on archival material. The preferred analyses are immunohistochemistry with fluorescent in situ hybridisation (FISH) as a follow up test for ambiguous results. Guidelines have been developed for standardised, well controlled procedures for the provision of reliable results. A group of three reference laboratories has been established to provide advice, quality assurance, and materials, where needed.
Collapse
Affiliation(s)
- I O Ellis
- Department of Histopathology, City Hospital, Hucknall Road, Nottingham NG5 1PB, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Abstract
BACKGROUND Psoriasis is a heterogeneous disease in its clinical expression. Both genetic and environmental factors are thought to contribute to the pathogenesis of the inflammatory and hyperproliferative components of the typical skin lesions. Predisposing genetic influences include associations with human leucocyte antigens (HLA) of which that with HLA-Cw6 is the strongest. Guttate psoriasis is a specific clinical manifestation of psoriasis frequently associated with group A beta-haemolytic streptococcal throat infection. OBJECTIVES We set out to determine whether further clinical subdivision of psoriasis is associated with tighter correlation with HLA-C alleles. PATIENTS/METHODS We determined the HLA-C locus genotype of 29 caucasian patients with guttate psoriasis presenting consecutively with guttate psoriasis associated with a history of a sore throat and/or an antistreptolysin O titre > 200 IU mL-1. Polymerase chain reaction typing using sequence-specific primers was used to detect all known HLA-C alleles. These data were compared with a control population of 604 random caucasian cadaver donors. RESULTS All patients (100%) with guttate psoriasis carried the Cw*0602 allele compared with 20% of the control population (odds ratio = infinity; 95% confidence limits 25.00-infinity; Pcorrected < 0.0000002). CONCLUSIONS This result is consistent with HLA-Cw*0602 playing a part directly in the pathogenesis of guttate psoriasis.
Collapse
Affiliation(s)
- E Mallon
- Tissue Typing Laboratory, Churchill Hospital, Oxford, U.K
| | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
OBJECTIVE To determine the contribution of urethral and skin flora to seminal fluid cultures and the relation between bacteriospermia and seminal leukocytes. DESIGN Prospective study. SETTING IVF-ET unit at a university teaching hospital. PATIENT(S) Sixty men starting an IVF-ET program. INTERVENTION(S) Culture of sequential first-catch urine, midstream urine, and semen samples with evaluation of seminal leukocytes. MAIN OUTCOME MEASURE(S) A comparison of microbes from first-catch urine, midstream urine, and semen samples and the correlations of seminal microbes, elevated leukocyte concentrations, and pregnancy. RESULT(S) Microorganisms were detected in 37% of first-catch urine samples, 27% of midstream urine samples, and 51% of semen samples. Most microorganisms were gram-positive microbes and were common to both urine and semen samples. Mean and median leukocyte concentrations were 0.98 x 10(6)/mL and 0.10 x 10(6)/mL, respectively. There was no correlation between seminal microbes and raised leukocytes or between leukocytospermia and/or bacteriospermia and pregnancy. CONCLUSION(S) Microorganisms are commonly found in insignificant quantities in the semen of asymptomatic men. The frequent isolation of gram-positive microbes common to both urine and semen and the absence of a correlation with raised leukocyte concentrations suggest that bacteriospermia most commonly represents contamination.
Collapse
Affiliation(s)
- E Cottell
- Royal College of Surgeons in Ireland, Academic Department of Obstetrics and Gynaecology, Rotunda Hospital, Dublin, Ireland.
| | | | | | | | | | | |
Collapse
|
41
|
Klassen AF, Newton JN, Mallon E. Measuring quality of life in people referred for specialist care of acne: comparing generic and disease-specific measures. J Am Acad Dermatol 2000; 43:229-33. [PMID: 10906643 DOI: 10.1067/mjd.2000.105507] [Citation(s) in RCA: 69] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
OBJECTIVE Our purpose was to compare 3 approaches to the measurement of quality of life in patients referred for specialist care of acne. METHODS A questionnaire was sent to 130 patients referred for management of their acne. Follow-up questionnaires were sent 4 and 12 months after treatment began. The questionnaire contained a generic index measure (EuroQol EQ-5D), a generic profile measure (Short Form 36), and a disease-specific measure (Dermatology Life Quality Index). Pretreatment results for the EQ-5D were compared with normative data. The responsiveness of the EQ-5D was compared with that of the other measures. RESULTS Before treatment, the sample reported substantially more pain/discomfort and anxiety/depression on the EQ-5D compared with a population sample. The disease-specific measure was more responsive to change compared with both generic measures. CONCLUSION Our study highlights the importance of combining information from generic measures with information from instruments designed specifically for use in people with skin disease.
Collapse
Affiliation(s)
- A F Klassen
- Centre for Community Health and Health Evaluation Research, University of British Columbia, Vancouver, Canada
| | | | | |
Collapse
|
42
|
Abstract
Psoriasis occurs with at least undiminished frequency in HIV-infected individuals. The behavior of psoriasis in HIV disease is of interest, in terms of pathogenesis and therapy because of the background of profound immunodysregulation. It is paradoxical that, while drugs that target T lymphocytes are effective in psoriasis, the condition should be exacerbated by HIV infection. The etiopathogenesis of psoriasis is unknown, but genetic and environmental factors are thought to be involved. There are controversial issues regarding the immunological basis of psoriasis and the role of CD4+ versus CD8+ T lymphocytes. Current opinion favors an autoimmune basis for psoriasis although the precipitating activating signal(s) within psoriatic plaques remains unknown. Candidate skin autoantigens that have cross-reactive determinants with bacterial antigens include keratins. The immunodysregulation resulting from HIV infection may trigger psoriasis in those genetically predisposed by the Cw*0602 allele. Because CD8 T cells recognize antigen in the context of class I molecules, the identification of a human leucocyte antigen (HLA) class I association in HIV-associated psoriasis strengthens the argument for an important role for CD8+ T lymphocytes in the immunopathogenesis of psoriasis. HLA-Cw*0602 could act as a cross-reactive target for cytotoxic T lymphocytes (CTLs) responding to processed peptides from microorganisms.
Collapse
Affiliation(s)
- E Mallon
- Department of Dermatology, Imperial College School of Medicine, Chelsea & Westminster Hospital, London, U.K
| | | |
Collapse
|
43
|
Abstract
This article illustrates the most common benign and malignant lesions in the breast, and is intended for the biologist working in the area of breast cancer and breast biology, not for the practicing pathologist. The atlas covers benign proliferative lesions, atypical lesions, variants of in situ cancer, the main types of invasive cancers, spindle cell lesions, and examples of vascular and lymphatic spread. Some entities are included to illustrate a point of particular relevance to the biology and histogenesis of the lesions. Some controversial diagnostic areas are considered, along with the relative risk of developing breast cancer associated with some of the proliferative lesions. The content of this atlas should be read in conjunction with the companion article by Howard and Gusterson in this issue. Their article covers the cellular origin of epithelial and stromal tumors and presents a description of some of the common benign proliferative lesions that are considered to be components of the normal spectrum of changes seen at postmortem or in biopsies.
Collapse
|
44
|
Abstract
CONTEXT It is well recognized that the presence of a foreskin predisposes to penile carcinoma and sexually transmitted infections. We have investigated the relationship between the presence or absence of the foreskin and penile dermatoses. OBJECTIVE To determine whether there is an association between circumcision and penile dermatoses. DESIGN A retrospective case control study of patients attending the department of dermatology with genital skin conditions. SUBJECTS The study population consisted of 357 male patients referred for diagnosis and management of genital skin disease. The control population consisted of 305 male patients without genital skin disease attending the general dermatology clinics over a 4-month period. MAIN OUTCOME MEASURES The relationship between circumcision and the presence or absence of skin disease involving the penis was investigated. The rate of circumcision in the general male dermatology population was determined. RESULTS The most common diagnoses were psoriasis (n = 94), penile infections (n = 58), lichen sclerosus (n = 52), lichen planus (n = 39), seborrheic dermatitis (n = 29), and Zoon balanitis (n = 27). Less common diagnoses included squamous cell carcinoma (n = 4), bowenoid papulosis (n = 3), and Bowen disease (n = 3). The age-adjusted odds ratio for all penile skin diseases associated with presence of the foreskin was 3.24 (95% confidence interval, 2.26-4.64). All patients with Zoon balanitis, bowenoid papulosis, and nonspecific balanoposthitis were uncircumcised. Lichen sclerosus was diagnosed in only 1 circumcised patient. Most patients with psoriasis, lichen planus, and seborrheic eczema (72%, 69%, and 72%, respectively) were uncircumcised at presentation. The majority of men with penile infections (84%) were uncircumcised. CONCLUSIONS Most cases of inflammatory dermatoses were diagnosed in uncircumcised men, suggesting that circumcision protects against inflammatory dermatoses. The presence of the foreskin may promote inflammation by a köebnerization phenomenon, or the presence of infectious agents, as yet unidentified, may induce inflammation. The data suggest that circumcision prevents or protects against common infective penile dermatoses.
Collapse
Affiliation(s)
- E Mallon
- Department of Dermatology, Imperial College School of Medicine, Chelsea & Westminster Hospital, London, England
| | | | | | | | | | | | | |
Collapse
|
45
|
Abstract
Human epidermal growth factor receptor 2 (HER2) is overexpressed, usually as a result of HER2 proto-oncogene amplification, in 20-30% of breast cancers. A HER2-positive status is generally associated with more aggressive disease and a worse prognosis. Furthermore, a positive HER2 status may predict the likelihood of resistance to some conventional therapies, as well as probably being predictive of sensitivity to anthracycline dose intensification. In addition to this prognostic/predictive value, HER2 is a target for specific therapy, with anti-HER2 monoclonal antibody therapy available in the USA. This article reviews the different assays used to determine HER2 status, discussing their relative advantages/disadvantages and the need for their standardisation before integration alongside other pathological indices into the clinical management of breast cancer.
Collapse
Affiliation(s)
- M Dowsett
- Academic Department of Biochemistry, Royal Marsden Hospital, London, UK.
| | | | | | | | | | | | | |
Collapse
|
46
|
|
47
|
Abstract
It has long been suggested that retroviral infection may play a role in the pathogenesis of autoimmune rheumatic disease. Particles resembling retroviruses have been reported in tissue from patients with Sjögren's syndrome, lupus and rheumatoid arthritis, and molecular mimicry between retroviral antigens and host proteins has been proposed as a mechanism of induction of autoimmunity. Since 1980, four distinct human infectious retroviruses have been discovered, HTLV-I, HTLV-II, HIV-1 and HIV-2. We recently cloned part of a new human retrovirus genome, designated human retrovirus-5 (HRV-5) and demonstrated that this is not endogenous and is therefore a novel infectious retrovirus. Because symptoms resembling arthritis, polymyositis and Sjögren's syndrome occur in individuals infected with HTLV-I and HIV-1, we investigated the possibility that HRV-5 was associated with idiopathic rheumatic disease. Using nested PCR, HRV-5 we demonstrated that proviral DNA was present in approximately 50% of synovial samples of arthritic joints and was also found in over 10% of blood samples of patients with rheumatoid arthritis and systemic lupus erythematosus. HRV-5 proviral DNA was not detectable in affected tissues of autoimmune diseases and was found in only one of over 200 tissues taken at autopsy from non-rheumatoid patients. Sequence analysis of the amplified viral segment showed genetic variation between samples with maintenance of the open reading frame typical of a replicating infectious retrovirus. Thus HRV-5 appears to be a human retrovirus found with a very low genome copy number in most tissues, but which is increased to detectable levels in inflamed joints and blood from patients with rheumatic disease. Whether HRV-5 is aetiologically important in these diseases remains to be determined.
Collapse
Affiliation(s)
- A Brand
- Chelsea and Westminster Hospital, London, UK
| | | | | | | | | |
Collapse
|
48
|
Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol 1999; 140:672-6. [PMID: 10233319 DOI: 10.1046/j.1365-2133.1999.02768.x] [Citation(s) in RCA: 270] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Skin diseases such as acne are sometimes thought of as unimportant, even trivial, when compared with diseases of other organ systems. To address this point directly, validated generic questionnaires were used to assess morbidity in acne patients and compare it with morbidity in patients with other chronic diseases. For 111 acne patients referred to a dermatologist, quality of life was measured using the Dermatology Life Quality Index, Rosenberg's measure of self-esteem, a version of the General Health Questionnaire (GHQ-28) and the Short Form 36 (SF-36). Clinical severity was measured using the Leeds Acne Grade. Population quality of life data for the SF-36 instrument were available from a random sample of adult local residents (n = 9334) some of whom reported a variety of long-standing disabling diseases. All quality of life instruments showed substantial deficits for acne patients that correlated with each other but not with clinically assessed acne severity. The acne patients (a relatively severely affected group) reported levels of social, psychological and emotional problems that were as great as those reported by patients with chronic disabling asthma, epilepsy, diabetes, back pain or arthritis. Acne is not a trivial disease in comparison with other chronic conditions. This should be recognized in the allocation of health care resources.
Collapse
Affiliation(s)
- E Mallon
- Department of Dermatology, Churchill Hospital, Headington, Oxford OX3 7LJ, U.K
| | | | | | | | | | | |
Collapse
|
49
|
Abstract
We report a case of dermatomyositis occurring in association with transitional cell carcinoma of the bladder. The case illustrates the importance of a thorough search for neoplasms in elderly patients with dermatomyositis and is a reminder that bladder cancer may be a rare cause of dermatomyositis. The case also shows that successful treatment of an underlying tumour may lead to resolution of paraneoplastic dermatomyositis, and relapse of cutaneous and muscle symptoms and signs may indicate recurrence of tumour.
Collapse
Affiliation(s)
- E Mallon
- Department of Dermatology, Chelsea and Westminster Hospital, London, UK
| | | | | | | | | | | |
Collapse
|
50
|
Griffiths DJ, Cooke SP, Hervé C, Rigby SP, Mallon E, Hajeer A, Lock M, Emery V, Taylor P, Pantelidis P, Bunker CB, du Bois R, Weiss RA, Venables PJ. Detection of human retrovirus 5 in patients with arthritis and systemic lupus erythematosus. Arthritis Rheum 1999; 42:448-54. [PMID: 10088767 DOI: 10.1002/1529-0131(199904)42:3<448::aid-anr9>3.0.co;2-8] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
OBJECTIVE To examine whether human retrovirus 5 (HRV-5) infection is associated with autoimmune rheumatic disease. METHODS DNA from patients with various disorders including inflammatory diseases and from normal subjects was tested by nested polymerase chain reaction (PCR) for HRV-5 proviral DNA. Positive results were confirmed by DNA sequencing. RESULTS HRV-5 proviral DNA was detected in 53% of synovial samples from arthritic joints, in 12% of blood samples from patients with rheumatoid arthritis (RA), and in 16% of blood samples from patients with systemic lupus erythematosus. In contrast, it was not detectable by PCR of affected tissues from patients with several other autoimmune diseases and was found in only 1 of >200 tissue specimens obtained at autopsy from non-RA patients. Sequence analysis of the amplified viral segment showed genetic variation between samples with maintenance of the open reading frame, typical of a replicating infectious retrovirus. CONCLUSION This is the first report of the frequent detection of HRV-5 in any disease. We propose that the possible involvement of HRV-5 in autoimmune and rheumatic disease should be investigated further.
Collapse
Affiliation(s)
- D J Griffiths
- Institute of Cancer Research, Chester Beatty Laboratories, London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|